Pharma BD Deal Intelligence
Roche paid $175M for Piramed's PI3K platform in 2008, but both derived oncology candidates—pictilisib and taselisib—failed in the clinic, with taselisib scrapped in 2018 after Phase III toxicity data. It took until 2024, a third drug generation and 16 years later, for Roche/Genentech to land an approved PI3K-alpha inhibitor, inavolisib—a distinct, internally discovered asset, not a Piramed compound.
Roche paid $175M for Piramed's PI3K platform; both derived oncology drugs (pictilisib, taselisib) failed in the clinic, and it took Roche/Genentech until 2024 — a third drug generation and 16 years later — to finally get a PI3K-alpha inhibitor (inavolisib) approved.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
FierceBiotech describes Roche's $175M Piramed grab as part of a 2008 dealmaking spree consolidating PI3K inhibitor rights.
C&EN positions the deal as a strategic doubling-down on PI3K, complementing Genentech's existing oncology partnership with Piramed.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
$160M upfront + $15M milestone; PI3K-alpha oncology, PI3K-delta inflammation
Roche paid $175M for Piramed's PI3K platform; both derived oncology drugs (pictilisib, taselisib) failed in the clinic, and it took Roche/Genentech until 2024 — a third drug generation and 16 years later — to finally get a PI3K-alpha inhibitor (inavolisib) approved.
Assessment window: 15yr post-close.
The phosphoinositide 3-kinase (PI3K) pathway is one of the most frequently dysregulated signaling axes in human cancer, with PIK3CA (encoding PI3K-alpha) mutated in ~30% of breast cancers, plus colorectal, endometrial and head-and-neck tumors. PI3K-delta is preferentially expressed in leukocytes and is a validated target for B-cell malignancies and inflammatory disease. In 2008 no PI3K inhibitor had been approved.
At the April 2008 deal date, the PI3K inhibitor field was nascent and crowded with discovery-stage programs: Novartis's BKM120/buparlisib and BYL719/alpelisib, Sanofi's XL765 (with Exelixis), Gilead/Calistoga's CAL-101 (later idelalisib), Semafore's SF1126, and academic-stage assets at the Institute of Cancer Research that ultimately powered Piramed's program. Piramed's lead PI3K-alpha asset GDC-0941 (later pictilisib) was already in Phase 1 under a 2005 Genentech option deal; PI3K-delta program targeted inflammation. Roche's acquisition consolidated upstream rights its Genentech subsidiary already partially controlled and locked out competitors from one of the most chemically advanced PI3K series of the era. Roche subsequently advanced GDC-0941 (pictilisib) and the related GDC-0980, while Novartis's alpelisib (Piqray, 2019) ultimately became the first selective PI3K-alpha inhibitor approved in PIK3CA-mutated HR+/HER2- breast cancer, and Gilead's idelalisib (Zydelig, 2014) the first PI3K-delta approval. Pictilisib itself did not reach approval, but the platform underpinned Roche's later PI3K beta and isoform-selective programs.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Piramed Pharma (this deal) | 2008 | $175M | 29 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2008 deals · Roche Holding AG deals